Transcatheter Arterial Chemoembolization Using Raltitrexed Plus Oxaliplatin For The Treatment Of The Middlelate Primary Hepatic Carcinomas:the Clinical Effect

purpose:This study observed and investigated the curative effect of raltitrexed combined with oxaliplatin in TACE of the primary liver cancer.Patients and Methods:83cases of primary liver cancer patients underwent TACE three times were selected as the research object in our hospital from June 2011 to July 2015.There are 48 cases inexperimental group, 35 cases in the control group, two groups were treated with TACE 3 times. Both groups using Seldinger technique to perform percutaneous femoral vein cathetherization and,to radiography inthe celiac axis, the hepatic artery, to clear the location,number, blood supply, size and range of the tumor, at the same time,there was no arteriovenous shunting.Selective catheterization to the tumor feeding artery and perfusion chemotherapy and embolization treatments are conducted.The short-term curative effect and adverse reactions of the two groups were observed.Results:The postoperative fever, pain, digestive system reactions in the experimental group are lower than those in the control group, the differences have statistical significance. Comparis ion of liver and kidney function,routine blood test result of the two groups before and after surgery confirmed that the differences in ALT, HB, WBC between the two groups were statistically significant. Some cases in the two groups appeared a transient change in liver and kidney function,routine blood test and returned to normal after a week. There were no serious adverse reactions and complications, such as rupture of liver cancer, pulmonary embolism, heart toxicity in the two groups .Two-year follow-up after TACE of the two groups showed that the median survival time of the experimental group is 18.1 months and the control group is 16.9 months.Two-year survival rate of the experimental group was slightly higher than that of the control group, but the differences have no statistical significance.Conclusion:The TACE of rraltitrexed combined with oxaliplatin in treatment of primary liver cancer is safe and effective. Compared with pirarubicin combined with oxaliplatin interventional therapy, it had mild adverse reaction. There were no significant difference in curative effect between the two groups at 6 months, 12months and 24 months- after treatment.